Close

Nabriva (NBRV) Reports Positive Topline Results from Phase 3 LEAP 1 Clinical Trial Evaluating IV and Oral Lefamulin

September 18, 2017 7:04 AM EDT Send to a Friend
Nabriva Therapeutics plc (NASDAQ: NBRV) today announced positive topline results from the lefamulin evaluation against pneumonia (LEAP 1) trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login